India Tightens Cough Syrup Sales, Hits OTC Drugmakers

India removed cough syrups from the list of drugs that can be sold without a prescription, tightening oversight on a product category that has long relied on loose distribution channels.

The change, part of an amendment to the Drugs Rules, 1945, takes cough syrups out of Schedule K – the blanket exemption that allowed sales outside licensed pharmacies. The government did not set a specific implementation timeline.

For Indian drugmakers that market cough syrups over the counter, the shift means a narrower distribution chain. Products that once moved through general stores and unregulated outlets now require a prescription or at minimum a sale through a licensed pharmacy. That could cut volumes and pressure margins for companies with high OTC exposure.

The move follows years of criticism that cough syrups have been subject to weaker oversight than other medicines, fostering self-medication. A letter in The Hindu Business Line this week made the point directly, calling the regulatory gap a persistent failure.

Which companies face the most risk? Those with large portfolios of codeine-based or simple cough preparations that sold without a prescription. The exact hit depends on how many brands relied on the Schedule K exemption. Drugmakers with low prescription dependency face the largest adjustment.

A delayed implementation or grandfathering of existing stock would reduce the immediate impact. A broader crackdown on other OTC categories or stricter prescription enforcement would amplify it.

The next concrete marker is the formal notification of the amended rules, which will specify any transition period. The Ministry of Health has not announced a date.